Home/Filings/4/0000950170-24-024920
4//SEC Filing

Warner Brent 4

Accession 0000950170-24-024920

CIK 0001661460other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 5:18 PM ET

Size

8.8 KB

Accession

0000950170-24-024920

Insider Transaction Report

Form 4
Period: 2024-03-01
Warner Brent
President, Gene Therapy
Transactions
  • Award

    Common Stock

    2024-03-01+80,743454,779 total
  • Tax Payment

    Common Stock

    2024-03-01$4.13/sh35,739$147,602419,040 total
  • Award

    Employee Stock Option (Right to Buy)

    2024-03-01+111,700111,700 total
    Exercise: $4.13Exp: 2034-02-28Common Stock (111,700 underlying)
Footnotes (3)
  • [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
  • [F2]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
  • [F3]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.

Documents

1 file

Issuer

Poseida Therapeutics, Inc.

CIK 0001661460

Entity typeother

Related Parties

1
  • filerCIK 0001910914

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 5:18 PM ET
Size
8.8 KB